Bausch Health Cos (NYSE:BHC) Stock Price Down 4% After Insider Selling

Bausch Health Cos Inc. (NYSE:BHC) shares traded down 4% during mid-day trading on Friday following insider selling activity. The stock traded as low as $6.54 and last traded at $6.54. 1,687,438 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 2,540,064 shares. The stock had previously closed at $6.81.

Specifically, insider Aimee J. Lenar sold 36,827 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total value of $258,893.81. Following the sale, the insider owned 334,853 shares in the company, valued at $2,354,016.59. This represents a 9.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BHC. Zacks Research downgraded Bausch Health Cos from a “hold” rating to a “strong sell” rating in a report on Friday, July 24th. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Royal Bank Of Canada lowered their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Finally, Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos News Roundup

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks upgraded BHC to a No. 2 (Buy) ranking, citing stronger earnings prospects and revisions that could support continued investor interest. Bausch Upgraded to Buy
• Positive Sentiment: Zacks Research raised several forward EPS estimates, including FY2027 earnings from $3.59 to $3.84 and FY2028 earnings from $3.02 to $3.04. Quarterly forecasts for 2027 and 2028 were also increased, reinforcing the earnings-revision catalyst. Rising Earnings Estimates
• Positive Sentiment: An analysis of Bausch + Lomb points to a potential turnaround driven by 9% year-over-year second-quarter revenue growth, margin expansion, stronger operating cash flow, and increased sales of higher-margin intraocular lenses and branded pharmaceuticals. These trends could aid EBITDA growth and deleveraging. Bausch Plus Lomb Analysis
• Neutral Sentiment: Analyst opinion remains mixed: Zacks Research still rates BHC “Strong Sell,” while the broader consensus is “Reduce” with an $8 target, limiting the impact of the more favorable Zacks Rank upgrade.
• Negative Sentiment: Insider Aimee Lenar sold 36,827 shares worth approximately $258,894, reducing her position by 9.91%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which makes it a weaker bearish signal but may still weigh modestly on sentiment. Insider Share Sale

Bausch Health Cos Trading Down 4.0%

The company’s fifty day simple moving average is $5.33 and its 200-day simple moving average is $5.46. The firm has a market capitalization of $2.45 billion, a PE ratio of -2.21 and a beta of 0.38. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.44 and a quick ratio of 1.08.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%.The firm had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. As a group, sell-side analysts expect that Bausch Health Cos Inc. will post 4.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Cos

Several hedge funds and other institutional investors have recently modified their holdings of BHC. Tidal Investments LLC lifted its holdings in shares of Bausch Health Cos by 2.6% in the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after purchasing an additional 1,276 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Bausch Health Cos by 14.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock valued at $98,000 after buying an additional 1,812 shares during the period. Jones Financial Companies Lllp purchased a new position in Bausch Health Cos during the second quarter worth about $148,000. Pictet Asset Management Holding SA raised its stake in shares of Bausch Health Cos by 4.1% during the 1st quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock worth $292,000 after buying an additional 2,114 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after acquiring an additional 2,552 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.